ResearcherMemorial Sloan Kettering Cancer CenterNo recent work listed
Danielle C. Glassman
Matched on ORCID iD 0000-0001-5376-6526; OpenAlex author ID A5027280259. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 26
2017: 2 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper
Papers 4
- Pancreatic cancer prognosis is predicted by an ATAC-array technology for assessing chromatin accessibility. Co-author DOI 10.1038/s41467-021-23237-2↗
- Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. Co-author DOI 10.1186/s12885-018-4605-1↗
- A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma. Co-author DOI 10.1002/cncr.30897↗
- Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical Phenotype. Co-author DOI 10.1158/1078-0432.ccr-17-0899↗
Closest collaborators
The 25 strongest of 26 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Eileen Mary O'Reilly · 3 shared papers, 2017–2018 · strength 0.18
- Paper Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experi… DOI 10.1186/s12885-018-4605-1↗
- Paper A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinom… DOI 10.1002/cncr.30897↗
- Paper Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical … DOI 10.1158/1078-0432.ccr-17-0899↗
- Kenneth H. Yu · 3 shared papers, 2017–2018 · strength 0.18
- Paper Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experi… DOI 10.1186/s12885-018-4605-1↗
- Paper A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinom… DOI 10.1002/cncr.30897↗
- Paper Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical … DOI 10.1158/1078-0432.ccr-17-0899↗
- Vinod P. Balachandran · 2 shared papers, 2017–2021 · strength 0.14
- Paper Pancreatic cancer prognosis is predicted by an ATAC-array technology for assessing chromatin accessibility. DOI 10.1038/s41467-021-23237-2↗
- Paper Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical … DOI 10.1158/1078-0432.ccr-17-0899↗
- Gökçe Aşkan · 2 shared papers, 2017–2021 · strength 0.14
- Paper Pancreatic cancer prognosis is predicted by an ATAC-array technology for assessing chromatin accessibility. DOI 10.1038/s41467-021-23237-2↗
- Paper Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical … DOI 10.1158/1078-0432.ccr-17-0899↗
- Steven D Leach · 2 shared papers, 2017–2021 · strength 0.14
- Paper Pancreatic cancer prognosis is predicted by an ATAC-array technology for assessing chromatin accessibility. DOI 10.1038/s41467-021-23237-2↗
- Paper Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical … DOI 10.1158/1078-0432.ccr-17-0899↗
- Christine A. Iacobuzio–Donahue · 2 shared papers, 2017–2021 · strength 0.14
- Paper Pancreatic cancer prognosis is predicted by an ATAC-array technology for assessing chromatin accessibility. DOI 10.1038/s41467-021-23237-2↗
- Paper Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical … DOI 10.1158/1078-0432.ccr-17-0899↗
- Anna M. Varghese · 2 shared papers, 2017–2018 · strength 0.13
- Paper Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experi… DOI 10.1186/s12885-018-4605-1↗
- Paper Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical … DOI 10.1158/1078-0432.ccr-17-0899↗
- Ghassan K. Abou‐Alfa · 2 shared papers, 2017 · strength 0.10
- Paper A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinom… DOI 10.1002/cncr.30897↗
- Paper Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical … DOI 10.1158/1078-0432.ccr-17-0899↗
- Maeve Aine Lowery · 2 shared papers, 2017 · strength 0.10
- Paper A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinom… DOI 10.1002/cncr.30897↗
- Paper Real-Time Genomic Profiling of Pancreatic Ductal Adenocarcinoma: Potential Actionability and Correlation with Clinical … DOI 10.1158/1078-0432.ccr-17-0899↗
- Alvin P. Makohon-Moore · 1 shared paper, 2021 · strength 0.09
- S. Dhara · 1 shared paper, 2021 · strength 0.09
- Rémy Nicolle · 1 shared paper, 2021 · strength 0.09
- Richard A. Moffitt · 1 shared paper, 2021 · strength 0.09
- S. Sinha · 1 shared paper, 2021 · strength 0.09
- Rohit Chandwani · 1 shared paper, 2021 · strength 0.09
- Jia Li · 1 shared paper, 2018 · strength 0.08
- Marinela Capanu · 1 shared paper, 2017 · strength 0.06
- David Paul Kelsen · 1 shared paper, 2017 · strength 0.06
- Olca Baştürk · 1 shared paper, 2017 · strength 0.05
- Emmet Jordan · 1 shared paper, 2017 · strength 0.05
- Brian T. Herbst · 1 shared paper, 2017 · strength 0.05
- Jaclyn Frances Hechtman · 1 shared paper, 2017 · strength 0.05
- Peter J. Allen · 1 shared paper, 2017 · strength 0.05
- William R. Jarnagin · 1 shared paper, 2017 · strength 0.05
- Leonard B. Saltz · 1 shared paper, 2017 · strength 0.05
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.